{"id":"NCT01852058","sponsor":"Allergan","briefTitle":"A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity","officialTitle":"Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-11","primaryCompletion":"2018-11-22","completion":"2019-10-03","firstPosted":"2013-05-13","resultsPosted":"2020-05-12","lastUpdate":"2020-05-12"},"enrollment":95,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Incontinence"],"interventions":[{"type":"BIOLOGICAL","name":"OnabotulinumtoxinA","otherNames":["BOTOX®","botulinum toxin Type A"]}],"arms":[{"label":"OnabotulinumtoxinA 50 U","type":"EXPERIMENTAL"},{"label":"OnabotulinumtoxinA 100 U","type":"EXPERIMENTAL"},{"label":"OnabotulinumtoxinA 200 U","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully completed Study 191622-120 (NCT01852045).","primaryOutcome":{"measure":"Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1","timeFrame":"Study Baseline (Prior to Day 1 in Study 120) to 2 consecutive days in the week prior to Week 6 in Treatment Cycle 1","effectByArm":[{"arm":"OnabotulinumtoxinA 50 U (Treatment Cycle 1)","deltaMin":2.66,"sd":0.876},{"arm":"OnabotulinumtoxinA 100 U (Treatment Cycle 1)","deltaMin":2.97,"sd":1.135},{"arm":"OnabotulinumtoxinA 200 U (Treatment Cycle 1)","deltaMin":3.99,"sd":5.492}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":30,"countries":["United States","Belgium","Canada","Czechia","France","Italy","Poland","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":31},"commonTop":["Urinary tract infection","Bacteriuria","Blood urine present","Pyrexia","Headache"]}}